Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Nothing changes

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Feb 28, 2022 3:58pm

140 Views

Post# 34468892

RE:RE:RE:Nothing changes

I should have also said that Paul has not done much for the sales of the legacy drugs but I don't really knock him for that as I think no one could have actually done any better than he did.

Bucknelly21 wrote: [what is paul actually responsible for that is so successful? Nash was not him, and neither was oncology, just wonding how you justify a fat salary wjile delivering nothing

quote=SPCEO1]Given that the bubble has been popped, retain investors have been hammered and the bull market is gone too, the chances of a really good stock price response to any positive information TH might report in the weeks ahead is far less than it once was. Since TH still has no effective research coverage and has yet to hire a IR person (I am sure all noticed an LSA was the MC on the conference call), it is not clear to me how the stock will get the sponsorship it needs to move significantly higher on good news. The trading volume recently has been totally dreadful as well as it is clear few other than ourselves are paying much attention to TH. Our CEO has done a lot of positive things but he has not even come close to fixing these issues with the marketing of the stock and the environment to now do so is much more difficult than it was through most of his now nearly 2 year tenure. From my perspective, it is a really big failure. He has given us the ONO, lower analyst coverage, lower trading volume and no sponsorship of the stock - if the Grumpy Grader came out from hibernation the only grade he could possibly give would be an F-. Since we are the people our CEO actually works for, it is hard to understand how this has not been a higher priority for him to get sorted out. And the board member added to appease grumpy shareholders has also not shown to be able to convince Paul of doing things more successfully either. Since Paul joined TH, the stock price has gone nowhere even though he has significantly improved the prospects of the company. In the end, if the stock price does not reflect the improvement, we may need a new CEO who has a better grasp on tying improving trends at the company to improving trends in the stock price.

The defense the company gives is that TH has greatly outperformed the XBI over the last year. Unfortunately, we cannot eat relative performance - we need the stock price to actually rise.

Bucknelly21 wrote: Despite learning many valuable lessons from the market and some analysts thera continues on the same non effective path in regards to transparency and market engagement. Do we really think that even if they get good results from the 1a/b that they will be able to capture the appreciation that would be due? Idk even if a Chinese partnership is announced they have not shown me they are capable of doing a good deal. I hope im wrong but im just going off past experience